Study of Copanlisib in Hepatic or Renal Impairment

Status:
Completed

Trial end date:
2020-05-15

Target enrollment:

Participant gender:

To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects

Phase 1

Bayer